Abstract:The clinical benefits of current antioxidant therapy for Alzheimer's disease (AD) are limited due to their poor disease target specificity. Our long-term objective is thus to design target-specific antioxidants and better understand their pharmacological mechanisms for AD and other human diseases, based on an emerging “pharmacophore conjugation” concept for drug development. The specific hypothesis for this studyl is that amyloid-targeting antioxidants assume targeted interdictions against cerebral Aβ amyloid pathology. We have rationally designed, synthesized, and characterized a novel bifunctional antioxidant- XH2A with chemically conjugated amyloid binding (benzothiazole) and antioxidant (lipoate) moieties. We have performed in sillico, cell culture and animal studies to characterize its partial pharmacological properties. In sillico, cellular, and animal studies on XH2A indicated that: (i) XH2A molecule has only one NH group (<5 hydrogen-bond donors), two N and one O atoms (<10 hydrogen bond acceptors), MW=414 (<500). It agrees well with the general Lipinski's Rule of Five; (ii) XH2A interacts with Aβ1-40 peptide computationally and has an affinity binding constant of KD=4.43 μM toward monomeric Aβ1-40 peptide as determined by the SPR (surface plasmon resonance) technique; (iii) XH2A has no neurotoxicity at low micromolar concentrations, and it interdicted amyloid precursor protein (APP) translation (via its 5'UTR, IC50=50 nM) in human SH-SY5Y cells and attenuated cerebral Aβ amyloid pathology in PS1/APP doubly transgenic mice without inducing apparent animal toxicity and behavior disturbances; (iv) BBB penetration studies indicated that XH2A brain concentration can reach 16 nM (via oral route, a single gavage dose of 25 mg/kg) in mouse brain in just 2 hours. This is approximately 32% of its IC50=50 nM, and its brain to plasma concentration ratio is around 1:2. XH2A interdicts Alzheimer's Aβ amyloidosis both in vitro and in vivo. Thus, XH2A could be a novel brain-permeable antioxidant targeting Alzheimer's amyloidosis.

Identification of two novel peptides with antioxidant activity and their potential in inhibiting amyloid-β aggregation in vitro.

Identification of Novel Antioxidant Peptide from Porcine Plasma Hydrolysate and Its Effect in in Vitro Digestion/hepg2 Cells Model

Identification of Novel Oligopeptides from the Simulated Digestion of Sea Cucumber (stichopus Japonicus) to Alleviate Aβ Aggregation Progression

Investigative on the Molecular Mechanism of Novel Antioxidation Peptides by 3D-QSAR, in Vitro Assay and MD Simulations

Studies on the Bioactivities and Molecular Mechanism of Antioxidant Peptides by 3D-QSAR, in Vitro Evaluation and Molecular Dynamic Simulations.

A Molecular Integrative Study on the Inhibitory Effects of WRR and ERW on Amyloid Β Peptide (1–42) Polymerization and Cell Toxicity

Exploring the Mechanisms of Anti‐Aβ42 Aggregation Activity of Walnut‐derived Peptides Using Transcriptomics and Proteomics in Vitro

Molecular Integrative Study on Inhibitory Effects of Pentapeptides on Polymerization and Cell Toxicity of Amyloid-β Peptide (1–42)

Identification of N-phenyl-3-methoxy-4-pyridinones As Orally Bioavailable H3 Receptor Antagonists and Β-Amyloid Aggregation Inhibitors for the Treatment of Alzheimer's Disease.

A Computational Study of Self-Assembled Hexapeptide Inhibitors Against Amyloid-Β (aβ) Aggregation.

Anti-Inflammatory Activity of 4-(4-(Heptyloxy)phenyl)-2,4-dihydro-3H-1,2,4-triazol-3-one via Repression of MAPK/NF-κB Signaling Pathways in β-Amyloid-Induced Alzheimer's Disease Models

Anti-Inflammatory Activity of 4-(4-(Heptyloxy)phenyl)-2,4-dihydro-3H-1,2,4-triazol-3-one via Repression of MAPK/NF-κB Signaling Pathways in β-Amyloid-Induced Alzheimer’s Disease Models

Extending Lifespan of Alzheimer’s Mode Nematode CL4176 Using a Novel Bifunctional Peptide with Inhibition of Β -Amyloid Aggregation and Anti-oxidation

Anti-Inflammatory Activity of 4-(4-(Heptyloxy)phenyl)-2,4-dihydro-3H-1,2,4-triazol-3-one via Repression of MAPK/NF-kappa B Signaling Pathways in beta-Amyloid-Induced Alzheimer's Disease Models

A BBB-permeable Antioxidant Targeting Alzheimer's Amyloidogenesis

A multifunctional peptide rescues memory deficits in Alzheimer's disease transgenic mice by inhibiting Aβ42-induced cytotoxicity and increasing microglial phagocytosis.

Structural Optimization and Biological Evaluation of Substituted Bisphenol A Derivatives As Beta-Amyloid Peptide Aggregation Inhibitors.

Pentapeptide WN5 Targets the Gut Microbiota in Alleviating Alzheimer’s Disease Pathologies

Macromolecular and small-molecule modulation of intracellular Aβ42 aggregation and associated toxicity.

Atomistic Characterization of Binding Modes and Affinity of Peptide Inhibitors to Amyloid-Β Protein

Investigation of Antioxidant Mechanisms of Novel Peptides Derived from Asian Swamp Eel Hydrolysate in Chemical Systems and AAPH-Induced Human Erythrocytes